Sandoz: An Interchangeability Labeling Requirement Should Apply To All Biologics

Novartis' biosimilar company Sandoz urged FDA to reject "in its entirety" AbbVie's citizen petition asking the agency to require that biosimilar drug labeling contain a clear statement that the product is a biosimilar and that it is licensed for fewer than all the reference product's conditions, among other requests. The move came a few days after AbbVie sent FDA a supplement to its petition reiterating its requests and also objecting to FDA's stance that interchangeability does not have to be...